Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer…

Read The Full Article…Therapies For Heart Disease And Cancer May Benefit From Snake Venom Studies Read more »

An international team of researchers that reviewed data from several trials found that taking calcium supplements was linked to a higher risk of heart attack and other cardiovascular events; the authors called for new research to re-assess the role of calcium supplements in the treatment of osteoporosis…

Read The Full Article…Calcium Supplements May Increase [...] Read more »

Vitamin D deficiency is associated with arterial stiffness, a risk factor for heart disease and stroke, in black teens according to a new study accepted for publication in The Endocrine Society’s Journal of Clinical Endocrinology & Metabolism (JCEM). Black teens taking vitamin D supplementation of 2,000 international units (IU) per day had a decrease in [...] Read more »

The $1 billion increase for the National Institutes of Health (NIH) approved by the Senate Appropriations Subcommittee is a much needed boost to heart disease and stroke research and a welcome source of revenue for the research community in this challenging fiscal environment…

Read The Full Article…Statement From American Heart Association President Ralph Sacco, M.D. On [...] Read more »

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) (“Angiotech”) and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack…

Read The Full Article…Angiotech Pharmaceuticals And Partner Athersys Announce Positive [...] Read more »

To improve emergency care for heart attack patients, new research suggests that expanding percutaneous coronary intervention (PCI) capacity at hospitals is less effective than using emergency medical services (EMS) to transport patients directly to existing PCI centers…

Read The Full Article…Transporting Patients Directly To PCI-Capable Hospitals Best Strategy For Treating Deadliest Heart Attack Read more »

Abbott received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin – the most commonly prescribed dose of simvastatin – with either 500 mg or 1,000 mg of niacin extended-release…

Read The Full Article…Abbott’s SIMCOR(R) (Niacin Extended-Release / [...] Read more »

Abbott (NYSE: ABT) received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR®, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin the most commonly prescribed dose of simvastatin with either 500 mg or 1,000 mg of niacin extended-release…

Read The Full Article…Abbott’s SIMCOR ® [...] Read more »

GlaxoSmithKline (GSK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arixtra (fondaparinux),an anti-clotting drug (antithrombotic) for the treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis (SVT) of the lower limbs without concomitant deep-vein thrombosis…

Read The Full Article…GSK Receives CHMP Positive Opinion For [...] Read more »

A new analysis led by researchers at UCSF shows that avoiding lowest-volume hospitals and maximizing adherence to quality care processes are both effective approaches to reducing costs associated with coronary bypass surgery…

Read The Full Article…Quality Coronary Bypass Care Can Improve Lives And Cut Costs Read more »